Program
eravacycline
Also written as “Eravacycline”, “IV Eravacycline 2mg/kg” and “IV Eravacycline 1.5mg/kg”.
Its studies are mostly in Intraabdominal Infections · Appendicitis · Urinary Tract Infections · Kidney Failure, Chronic · Bacterial Infections, led by Tetraphase Pharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Tetraphase Pharmaceuticals | 101 open or running | phase 3since Apr 29, 2013 | Dec 21, 2010 | Feb 17, 2029phase 2 · NCT06794541 |
Also a collaborator on its studies: innoviva-specialty-therapeutics.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 21, 2010First study: phase 2 study in Complicated Intra-abdominal InfectionFirst studyNCT01265784 · 143 enrolled · United States, Bulgaria, India and more
- Apr 29, 2013Phase 3 study in Complicated Intra-abdominal InfectionsNCT01844856 · 541 enrolled · United States, Argentina, Bulgaria and more
- Sep 10, 2013Phase 1 study in Normal Drug ToleranceNCT01989949 · 20 enrolled · United States
- Oct 28, 2013Phase 3 study in cUTINCT01978938 · 908 enrolled · United States, Bulgaria, Colombia and more
- May 5, 20142 phase 1 studiesNCT02135302, NCT02135276
- May 23, 2016Phase 3 study in Complicated Intra-abdominal InfectionsNCT02784704 · 500 enrolled · United States, Bulgaria, Czechia and more
- Jan 17, 2017Phase 3 study in Complicated Urinary Tract InfectionsNCT03032510 · 1,205 enrolled · United States, Austria, Bulgaria and more
- Sep 26, 2018Phase 1 study in Bacterial InfectionsNCT03696550 · 19 enrolled · United States
- Jan 15, 2025Phase 2 study in Complicated Intra-abdominal Infections (cIAI)NCT06794541 · 35 planned · United States
Ahead
- Feb 17, 2029Primary completion: phase 2 study in Complicated Intra-abdominal Infections (cIAI)NCT06794541
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Bacterial 70S ribosome inhibitor; Bacterial 70S ribosome inhibitor”ChEMBL 37, by rule
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06794541Complicated Intra-abdominal Infections (cIAI) · United States | 2 | Recruiting | Feb 17, 2029 | 35 |
| NCT03696550Bacterial Infections · United States | 1 | Completed | Mar 14, 2021 | 19 |
| NCT03032510Complicated Urinary Tract Infections · United States, Austria, Bulgaria and more | 3 | Completed | Dec 2017 | 1,205 |
| NCT02784704Complicated Intra-abdominal Infections · United States, Bulgaria, Czechia and more | 3 | Completed | May 8, 2017 | 500 |
| NCT02135302Impaired Hepatic Function · United States | 1 | Completed | Feb 2014 | 24 |
| NCT02135276Kidney Failure, Chronic | 1 | Completed | Mar 2014 | 12 |
| NCT01978938cUTI · United States, Bulgaria, Colombia and more | 3 | Completed | Jun 3, 2015 | 908 |
| NCT01989949Normal Drug Tolerance · United States | 1 | Completed | Jan 2013 | 20 |
| NCT01844856Complicated Intra-abdominal Infections · United States, Argentina, Bulgaria and more | 3 | Completed | Aug 2014 | 541 |
| NCT01265784Complicated Intra-abdominal Infection · United States, Bulgaria, India and more | 2 | Completed | May 2012 | 143 |
How it is read
Names in the registry
- “Eravacycline”, 4 entries
- “eravacycline”, 2 entries
- “IV Eravacycline 2mg/kg”, 1 entry
- “IV Eravacycline 1.5mg/kg”, 1 entry
- “TP-434”, 1 entry
Conditions, from the studies’ own filings
- Intraabdominal Infections, 3 studies
- Appendicitis, 1 study
- Urinary Tract Infections, 1 study
- Kidney Failure, Chronic, 1 study
- Bacterial Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.